To date, preterm infants with respiratory distress syndrome (RDS) after birth have been managed with a combination of endotracheal intubation, surfactant instillation, and mechanical ventilation. It is now recognized that noninvasive ventilation (NIV) such as nasal continuous positive airway pressure (CPAP) in preterm infants is a reasonable alternative to elective intubation after birth. Recently, a metaanalysis of large controlled trials comparing conventional methods and nasal CPAP suggested that CPAP decreased the risk of the combined outcome of bronchopulmonary dysplasia or death. Since then, the use of NIV as primary therapy for preterm infants has increased, but when and how to give exogenous surfactant remains unclear. Overcoming this problem, minimally invasive surfactant therapy (MIST) allows spontaneously breathing neonates to remain on CPAP in the first week after birth. MIST has included administration of exogenous surfactant by intrapharyngeal instillation, nebulization, a laryngeal mask, and a thin catheter. In recent clinical trials, surfactant delivery via a thin catheter was found to reduce the need for subsequent endotracheal intubation and mechanical ventilation, and improves short-term respiratory outcomes. There is also growing evidence for MIST as an alternative to the INSURE (intubation-surfactantextubation) procedure in spontaneously breathing preterm infants with RDS. In conclusion, MIST is gentle, safe, feasible, and effective in preterm infants, and is widely used for surfactant administration with noninvasive respiratory support by neonatologists. However, further studies are needed to resolve uncertainties in the MIST method, including infant selection, optimal surfactant dosage and administration method, and need for sedation.
Introduction
Respiratory distress syndrome (RDS) is a major cause of neonatal respiratory morbidity and mortality. For many years, neonates with RDS have been managed with a combination of tracheal intubation and surfactant replacement therapy (SRT) administered with mechanical ventilation. SRT in preterm infants has been proven effective in reducing pulmonary morbidity and mortality, and has been a major treatment in intubated preterm infants with respiratory distress after birth 1, 2) . There have been many studies on the timing of surfactant administration for newborns with RDS. In the late 1990s and early 2000s, prophylactic SRT showed decreased respiratory morbidity (relative risk [RR] , 0.69; 95% confidence interval [CI] , 0.55-0.86) and mortality (RR, 0.84; 95% CI, 0.74-0.95), compared with delayed selective surfactant treatment for neonatal RDS 3, 4) , and prophylactic use of surfactant became widely accepted. However, intubation itself may cause adverse effects and positive pressure ventilation after tracheal intubation may also increase acute lung injury in preterm infants 5) . Therefore, noninvasive ventilation such as continuous positive airway pressure (CPAP) has been intro duced as a primary treatment for preterm infants with spontaneous breathing after birth for the purpose of reducing acute lung injury. CPAP treatment in preterm infants was more likely to have good short and longterm outcomes, compared with intubation, positive pressure ventilation, and surfactant application 610) . Three metaanalyses showed that primary CPAP therapy may decrease the incidence of bronchopulmonary dysplasia (BPD) 1113) . These results led the Euro pean Association of Perinatal Medicine and the American Academy of Pediatrics to recommend use of noninvasive ventilation for pri mary respiratory support in preterm infants with respiratory distress 14, 15) . There has been a rapid increase in the use of CPAP as primary therapy for preterm infants with respiratory distress, but whether and how to give surfactant to nonintubated infants re mains unclear 16) . The intubationsurfactantextubation (INSURE) technique was the first method to overcome the CPAPsurfactant dilemma. Ver der et al. 1719 ) published 2 randomized controlled trials using the INSURE method, which has subsequently been widely accepted in Scandinavia. Recently, the INSURE procedure has been reported to reduce the need for further intubation and duration of mechanical ventilation 2022) . However, the need for sedative medication, secondary effects such as bradycardia or hypotension, and difficulty in extubation remain problems in the INSURE technique, and many neonatologists are investigating noninvasive or minimally invasive methods for sur factant administration, to avoid tracheal intubation and sedation 23, 24) . Minimally invasive surfactant therapy (MIST) is also called less in vasive surfactant administration. These MIST methods include intrapharyngeal surfactant instillation 25) , surfactant nebulization 26) , surfactant instillation via a laryngeal mask 27) , and surfactant instilla tion via a thin endotracheal catheter 28) , among which the most com mon method is tracheal catheterization 16, 29, 30) . Recent reviews up dated several MIST methods based on feasibility studies, cohort studies, and clinical trials.
Different MIST methods
There are four different MIST methods, i.e., pharyngeal surfac tant administration, aerosolized surfactant administration, laryn geal maskguided surfactant administration, and surfactant ad ministration via a thin catheter 31) . The timeline of the 4 different techniques for surfactant administration is shown in Table 1 as a modified metanarrative review by More et al. 31) .
Surfactant Instillation into the pharynx
Intrapharyngeal surfactant instillation is the oldest approach in which a pulmonary surfactant is injected into the pharynx before the first breath and spreads at the airfluid interface when the preterm infant starts breathing. Surfactant application into the pharynx was first applied by Enhoerning and Robertson in 1972 using a premature rabbit model, and the results showed that this procedure was effective in improving lung function in preterm rabbits 59) . In 1987, a randomized trial of intrapharyngeal instillation was first performed in humans by the Ten Centre Study Group 32) . Dambeanu et al. 33) performed a randomized multicenter clinical pilot study:
intrapharyngeal surfactant instillation after birth versus routine surfactant application in preterm infants with gestational age 28-33 weeks. A feasibility and safety study of 23 preterm infants born at 27-30 weeks of gestation was done by Kattwinkel et al. 25) in 2004.
In 2011, Cochrane Reviews showed that surfactant application into the pharynx before the first breath is potentially feasible, safe, and may be effective, but there were no welldesigned randomized con trolled trials 60) . Table 2 shows the characteristics of these human studies 25, 32, 33) . , 1987* Jorch et al. 34) , 1997 Brimacombe et al. 38) , 2004 † Verder et al. 44) , 1992
Dambeanu et al. 33) , 1997* Arroe et al. 35) , 1998 Trevisanuto et al. 27) , 2005 † Kribs et al. 28, 29, 45) , 2007, 2008, 2010 Kattwinkel et al. 25) , 2004 Berggren et al. 26) , 2000* Micaglio et al. 39) , 2008 † Göpel et al. 46) , 2011* Finer et al. 36) , 2010 Barbosa et al. 40) , 2012 † Dargaville et al. 47, 48) , 2011, 2013
Minocchieri et al. 37) , 2013* Attridge et al. 41) , 2013* Mehler et al. 49) , 2012
Sadeghnia et al. 42) , 2014* Kanmaz et al. 50) , 2013* Pinheiro et al. 43) , 2016* Klebermass-Schrehof et al. 24) , 2013
Heidarzadeh et al. 51) , 2013* Aguar et al. 52) , 2014
Kribs et al. 53) , 2015* Mohammadizadeh et al. 54) , 2015* Bao et al. 55) , 2015* Krajewski et al. 56) , 2015
Göpel et al. 57) , 2015
Canals Candela et al. 58) , 2016
LMA, laryngeal mask airway. *Prospective randomized controlled trials. † Case reports or case series. Normal: Observational studies with or without control group.
Surfactant nebulization
Surfactant nebulization is an old concept that appeared to be an attractive alternative technique of surfactant application, and was called noninvasive surfactant therapy. A nebulizer is used to admi nister the pulmonary surfactant in aerosolized form. Admini stration as an aerosol is limited by many technical problems: particle size 0.5 to 2.0 mm, stability during the process of nebulization, and loss of surfactant 61) . Thus, various types of nebulizers have been studied for surfactant administration. Fok et al. 62 ) tested a jet nebulizer and an ultrasonic nebulizer in an animal model, and con cluded that these types of nebulizers were not effec tive for SRT. Three feasibility studies and 2 randomized trials using surfactant nebulization in humans were published. Four of these studies used a jet nebulizer and one used a vibrating membrane aerosolization system. These trials suggested that nebulized surfactant is safe and fea sible, with some evidence for clinical improvement 63) . However, many questions remained unanswered: the proper positioning of the nebulizer in the circuit, the suitable interface for noninvasive respi ra tory support during nebulization, the optimal surfactant prepa ration and dosing, and the group of preterm infants most likely to benefit from aerosolized surfactant 61) . Welldesigned and appropriately powered, multicenter, randomized controlled trials are needed. How ever, nebulization is the preferred technique to avoid manipula tion of the airways during surfactant administration. Table 3 shows the human studies to date 27, 3843) .
Surfactant administration via a thin catheter (tracheal cathe terization)
There are 2 basic methods for surfactant instillation via a thin catheter: the Cologne method and the Hobart method 45, 47, 52) . Other methods are variations of the above two methods. Table 5 shows the techniques of tracheal catheterization for surfactant administration 16, 24, 28, 47, 48, 50, 52) . Surfactant administration through tracheal catheterization was first described by Verder et al. 44) , who used it as an alternative to the INSURE technique. In 2007, Kribs et al. 28) performed and published the first feasibility study using the Cologne method (Fig. 1) , in which characteristics of these studies 26, 3437) .
Surfactant instillation via laryngeal mask
In 2004, Brimacombe et al. 38) described the feasibility of using a laryngeal mask for SRT in a report of 2 cases. This was followed by several case reports and randomized trials 27, 3941) . Attridge et al. 41) compared surfactant application via laryngeal mask and CPAP alone in a randomized controlled trial including 26 neonates with respiratory distress and a birth weight more than 1,200 g. In 2 more recent reports, randomized trials of instillation of surfactant through a laryngeal mask and the INSURE technique were compared 42, 43) . These 2 studies showed that there were no differences in shortterm outcomes between the 2 groups. Table 4 provides an overview of Korean J Pediatr 2017;60(9):273-281 a 4 to 5FG feeding tube and Magill forceps are used to introduce a thin catheter past the vocal cords. This procedure is part of a com plete intervention aimed at avoidance of tracheal intubation and positive pressure ventilation during the first 72 hours after birth 29, 49) . Further singlecenter and multicenter observational studies using the Cologne method have been performed.
In 2011, Dargaville et al. 47, 48) modified this procedure without using a Magill forceps and called it the Hobart method. Dargaville et al. 47, 48) evaluated 2 observational studies using the Hobart method for instillation of surfactant via an angiocatheter. The above 2 ob servational studies demonstrated rapid and sustained impro vement in oxygenation and reduction in duration of oxygen supplementa tion and need for early mechanical ventilation, but there were no differences in overall duration of ventilation and incidence of BPD. A large, randomized controlled trial of MIST using the Hobart method in preterm infants (the OPTIMISTA trial) is underway 64) . The OPTIMISTA trial is a multicenter, randomized controlled trial of surfactant application via a vascular catheter in preterm infants on CPAP, born at 25 to 28 weeks of gestation. Inclusion criteria are age less than 6 hours after birth and need for CPAP with a fraction of inspired oxygen (FiO 2 ) no less than 0.3. The intervention group rece ives surfactant (poractant alfa, 200 mg/kg) via the Hobart method, and the control group remains on CPAP.
All feasibility and cohort studies on surfactant administration via a thin catheter are shown in Table 6 , and the 7 randomized controlled trials are shown in Table 7 .
Problems to be solved in the future
Infant selection
Not all preterm infants on CPAP show good results with MIST. Many preterm infants with mild RDS are well managed with CPAP alone. On the contrary, some infants with moderate to severe RDS start on CPAP, but should ideally receive prophylactic or early re scue surfactant replacement to gain the most advantage 65) . However, infants with significant RDS must be treated to obtain the best effect with MIST. As a clinical predictive tool, FiO 2 thresholds of 0.30 and 0.40 were used in the AMV trial and Take Care study, respective ly 46, 50) . The possible role of a functional surfactant assay such as the stable microbubble test of gastric aspirate is an important area for future investigation 16) .
The MIST technique
Although there are many studies about each of the MIST techni ques, there is no study comparing the various methods. All MIST should be conducted by clinicians with proper training and experi ence to reduce the failure rate and perform the procedure success fully. The development of a suitable surfactant and a method for surfactant aerosolization are required. A purposebuilt surfactant ad 
Dose and preparation
The dosage of surfactant in spontaneously breathing infants should be considered, because MIST has to be performed relatively rapidly and reflux of surfactant is seen frequently 16) . Published stud ies recommend a surfactant dosage of either 100 or 200 mg/kg, but 200 mg/kg is recommended for a more prolonged effect 30) . Fur ther studies are needed to determine the optimal surfactant dose and to verify that administration of a relatively large volume (4-5 mL/kg) is safe and effective for MIST 16) .
Safety
Shortterm adverse effects such as cough, nausea, vomiting, re flux, apnea, bradycardia, and desaturation are common 61, 66) . More over, the need for positive pressure ventilation via facial mask, retrial or failure, unilateral surfactant deposition, mucosal bleeding, lung ministration apparatus such as a laryngeal mask or tracheal ca theter should be developed and tested to avoid offlabel use of me dical devices. Finally, the introduction of a video laryngoscope should be considered in order to determine the exact location of application and to verify success of the MIST technique 16) .
Premedication
Premedications used in MIST techniques include oral sucrose, atropine, opioids, ketamine, propofol, caffeine, morphine, fentanyl, muscle relaxants, and lidocaine spray 16, 66) . According to a European survey published in 2017, 52% of neonatologists did not use any form of premedication for MIST 66) . In general, administration of narcotic agents in the INSURE method is common, but the avoi dance of narcotics does not seem to have been associated with any shortterm deleterious effects 67) . In the MIST technique, spontaneous breathing plays a major role in the distribution of pulmonary sur factant, so the reduction of breathing effort by narcotics may be Decrease CPAP failure from 46% to 25% Survival increased significantly between periods 0 and 1 from 76% to 90% and survival without BPD rose from 65% to 80%.
Kribs et al. 45) , 58) , 2016
Prospective cohort study CPAP, ET instillation (n= 28)
MIST (n=19) ET intubation within 72 hr 42% I vs. 54% C (P< 0.05).
ET, endotracheal; MIST, minimally invasive surfactant therapy, ELBW, extremely low birth weight; GA, gestational age; FiO 2 , a fraction of inspired oxygen; BPD, bronchopulmonary dysplasia; I, intervention; C, control; NS, nonspecific; CPAP, continuous positive airway pressure; VLBW, very low birth weight; FiO 2 , a fraction of inspired oxygen; SD, standard deviation; MV, mechanical ventilation; IVH, intraventricular hemorrhage; OR, odds ratio; CI, confidence interval; CLD, chronic lung disease; INSURE, intubation, surfactant and extubation.
Korean J Pediatr 2017;60(9):273-281 bleeding, gastric deposition, and airway obstruction may occur during or after the MIST procedure 61, 66) . Some studies suggested that the MIST technique may be associated with increased risk of necrotizing enterocolitis or spontaneous intestinal perforation, but additional largescale, randomized controlled trials are needed to confirm the above association 53, 57) . There have been 2 longterm followup studies of infants treated with MIST. Porath et al. 67) performed a 6year followup of a feasi bility cohort study. The survival rate and disabilityfree rate in the intervention group tended to be higher than in the control group. Teig et al. 68) also published a 36month followup of infants treated with MIST. This study showed that the intervention group performed better on the Bayley Scales Mental Developmental Index and Psychomotor Developmental Index than a historical control group.
Conclusions
MIST is a method of surfactant administration without intubation in spontaneously breathing preterm infants with RDS. There are four different MIST methods, i.e., surfactant administration by in trapharyngeal instillation, aerosolization, laryngeal mask, and tracheal catheterization. There is growing evidence for surfactant instillation via a laryngeal mask as an alternative to the INSURE procedure. Several clinical studies showed an advantage of MIST via tracheal catheterization over either CPAP alone or surfactant appli cation via INSURE technique; moreover, MIST via catheter applica tion seems gentle, safe, feasible, and effective in preterm infants with RDS. Intrapharyngeal surfactant instillation and surfactant nebulization are less invasive, but there are few data to recommend these methods. Further studies are needed to resolve uncertainties of the MIST method, including appropriate infant selection, optimal surfactant dosage and administration method, and need for seda tion.
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